SALT LAKE CITY, Feb. 9, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a study published in Lancet Oncology shows the Company's 46-gene PROLARIS™ molecular diagnostic test significantly predicts prostate cancer outcome. The study demonstrated that a patient's cell cycle progression (CCP) score is a strong indicator of the risk of disease recurrence and death in patients diagnosed with prostate cancer and may play an essential role in determining the appropriate treatment for patients with prostate cancer. The study will appear in an article, entitled "Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study."
